119th Congress · introduced in the House · Mar 19, 2026
ISLET Act
Official title from Congress.gov
Latest action (Mar 19, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
4 citations.
BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.) · lobbying firm or registrant: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$150,000
Spent on own lobbying
H.R. 10227, the INSULIN Act and Issues pertaining to FDA modernization; S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to grant fu…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · lobbying firm or registrant: TARPLIN, DOWNS & YOUNG, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$40,000
Paid to lobbying firm
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diab…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.) · lobbying firm or registrant: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$220,000
Spent on own lobbying
…INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.) · lobbying firm or registrant: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$280,000
Spent on own lobbying
…the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertain…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing